Valneva

VLA

FR0004056851

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 09:09:00 08/07/2024 pm IST			5-day change	1st Jan Change
3.188 ^EUR	-0.44%		-2.03%	-32.46%

01/07	Valneva's Secures Marketing Authorization in Europe for Chikungunya Vaccine	MT
01/07	New semester, new state of mind

Valneva SE announced that it has received €15 million in funding from NB Alternatives Advisers LLC

January 31, 2015

Valneva SE (ENXTPA:VLA) announced that it has received €15 million in loan facility from new lender Athyrium Opportunities Fund II LP, a fund managed by NB Alternatives Advisers LLC in January 2015.

Latest news about Valneva

Valneva's Secures Marketing Authorization in Europe for Chikungunya Vaccine	01/07	MT
New semester, new state of mind	01/07
Valneva SE Receives Marketing Authorization in Europe for the World's First Chikungunya Vaccine, Ixchiq	01/07	CI
Valneva: Marketing authorization granted to Ixchiq in Europe	01/07	CF
Valneva's Chikungunya Vaccine Secures Approval for Use in EU	28/06	MT
Valneva SE Appoints Daniele Guyot-Caparros as Board of Directors	26/06	CI
Valneva's Chikungunya Vaccine Receives Health Canada's Approval	24/06	MT
Valneva rises after Canadian approval for its chikungunya vaccine	24/06	RE
Valneva Secures Canadian Approval for Chikungunya Vaccine	24/06	MT
Europe opens hesitant as metal prices fall	24/06	RE
Valneva: Ixchiq approved in Canada	24/06	CF
Pfizer: article on Lyme vaccine in The Lancet	04/06	CF
Valneva: article on Lyme vaccine in The Lancet	04/06	CF
Valneva SE Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases	03/06	CI
Valneva: positive opinion from the CHMP in chikungunya	03/06	CF
Valneva's Chikungunya Vaccine Gains Support From EU Regulator Committee	31/05	MT
Valneva SE Receives EMA?s Positive CHMP Opinion for its Chikungunya Vaccine	31/05	CI
EU regulator recommends use of Valneva's chikungunya vaccine	31/05	RE
Valneva Se Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer	22/05	CI
Valneva Names New Chief Scientific Officer	21/05	MT
Valneva appoints Scientific Director	21/05	CF
Valneva: new positive data in CHIKV	13/05	CF
Valneva SE Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05	CI
Transcript : Valneva SE, Q1 2024 Earnings Call, May 07, 2024	07/05
Europe rises, buoyed by financial results	07/05	RE

Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The group takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets two proprietary travel vaccines as well as certain third-party vaccines leveraging its established commercial infrastructure. Revenues from its growing commercial business help fuel the continued advancement of Valneva's vaccine pipeline. This includes the world's first vaccine against the chikungunya virus and the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, as well as vaccine candidates against the Zika virus and other global public health threats.

Sector

Biotechnology & Medical Research

Calendar

13/08/2024 - Q2 2024 Earnings Release

Related indices

CAC Mid 60

More about the company

Income Statement Evolution

More financial data

Ratings for Valneva

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.188 EUR

Average target price

8.633 EUR

Spread / Average Target

+170.81%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
VALNEVA	-32.46%	482M
MODERNA, INC.	+17.09%	45.34B
LONZA GROUP AG	+42.10%	40.42B
IQVIA HOLDINGS INC.	-9.70%	37.92B
ALNYLAM PHARMACEUTICALS, INC.	+33.28%	31.75B
CELLTRION, INC.	-8.98%	27.71B
ICON PUBLIC LIMITED COMPANY	+13.37%	26.52B
UNITED THERAPEUTICS CORPORATION	+44.11%	13.96B
MEDPACE HOLDINGS, INC.	+32.33%	12.44B
BIO-TECHNE CORPORATION	-7.26%	11.26B

Other Biotechnology & Medical Research

Valneva

Equities

VLA

FR0004056851

Biotechnology & Medical Research

Valneva SE announced that it has received €15 million in funding from NB Alternatives Advisers LLC

Latest news about Valneva

Chart Valneva

Company Profile

Income Statement Evolution

Ratings for Valneva

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research